샘플 요청 목록

 카트 문의
시장보고서
상품코드
1513886

림프종 치료제 시장

Lymphoma Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 406 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

림프종 치료제 세계 시장은 2030년까지 252억 달러에 달할 전망

2023년에 161억 달러로 추정된 림프종 치료제 세계 시장은 2030년에는 252억 달러에 이르고, 분석 기간 2023-2030년의 CAGR은 6.6%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 비호지킨 림프종(NHL) 치료제는 CAGR 6.4%로 성장을 지속하고, 분석 기간 종료까지 205억 달러에 달할 것으로 예측됩니다. 호지킨 림프종(HL) 치료제 부문의 성장률은 분석 기간 동안 CAGR 7.8%로 추정됩니다.

미국 시장은 43억 달러, 중국은 CAGR 10.7%로 성장할 것으로 예측

미국의 림프종 치료제 시장은 2023년 43억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 57억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 10.7%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.4%와 6.9%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 3.7%로 성장할 것으로 예측됩니다.

림프종 치료제 - 주요 동향 및 촉진요인

림프종 치료제는 림프계에서 발생하는 암의 일종인 림프종에 대한 다양한 치료 옵션을 포함하고 있습니다. 림프종에는 주로 호지킨 림프종(HL)과 비호지킨 림프종(NHL)의 두 유형가 있으며, 후자 쪽이 일반적입니다. 림프종 치료는 전통적인 화학 요법과 방사선 요법에서보다 표적화 된 효과적인 선택으로 해마다 크게 진화하고 있습니다. 리툭시맙과 같은 단클론항체는 특히 비호지킨 림프종에서 암세포 표면의 특정 단백질을 표적으로 함으로써 획기적인 변화를 가져왔습니다. 또한, 체크포인트 억제제 및 CAR-T 세포 요법을 포함한 면역요법의 진보는 치료의 새로운 길을 열어 기존의 치료에 반응하지 않는 환자에게 희망을 가져왔습니다. 이들 치료법은 신체의 면역계를 이용하여 암과 보다 효과적으로 싸우는 것으로, 임상시험에서 유망한 결과를 나타내어 환자의 생존율의 향상과 생활의 질의 개선으로 이어졌습니다.

림프종 치료제의 또 다른 중요한 진보는 암 진행에 관여하는 특정 유전자 변이 및 세포 경로에 초점을 맞춘 표적 요법의 개발입니다. 브렌툭시맙 베도틴이나 이브루티닙과 같은 약제는 암세포의 증식과 생존의 메커니즘을 저해함으로써 다양한 형태의 림프종 치료에 효능을 나타내고 있습니다. 이러한 치료는 종종 효과를 높이고 내성의 가능성을 줄이기 위해 기존의 치료와 함께 사용됩니다. 게다가, 차세대 시퀀서와 같은 진단 기술의 진보는 림프종의 특정 유전자 변화를 확인하는 능력을 향상시키고, 보다 개별화된 정확한 치료 계획을 가능하게 했습니다. 이 정밀의료 접근법은 치료 성적을 향상시킬 뿐만 아니라 환자 한 명 한 명의 암의 특징에 맞춘 치료가 가능하므로 부작용을 최소화할 수 있습니다.

림프종 치료제 시장의 성장은 여러 요인에 의해 발생합니다. 첫째, 특히 노화 사회에서 림프종의 이환율이 증가함에 따라 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 둘째, 생명공학과 의약품의 기술 진보는 새로운 치료법의 개발을 가속화하고 이용 가능한 치료법의 선택을 넓히고 있습니다. 셋째, 표적 치료제와 면역요법의 성공은 연구개발에 많은 투자를 불러들여 경쟁적이고 혁신적인 시장환경을 키우고 있습니다. 게다가 획기적인 치료법이 규제 당국으로부터 승인됨으로써 환자가 첨단 치료를 받을 수 있게 되었습니다. 또한 조기 진단 및 개인화 치료의 이점에 대한 환자와 건강 관리 제공업체의 인식이 증가하고 있으며, 이는 시장 수요를 더욱 밀어 올리고 있습니다. 마지막으로 신흥국의 헬스케어 인프라 확대와 선진적인 진단·치료기술의 채용이 세계적으로 진행되고 있는 것이 시장의 지속적 성장을 확실히 하고 있습니다. 이러한 요인들이 결합되어 림프종 치료제는 역동적이고 빠르게 진화하고 있으며 지속적인 진보와 환자의 예후 개선이 기대되고 있습니다.

조사 대상 기업 예(총 93건)

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Forma Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Seattle Genetics, Inc.
  • Spectrum Pharmaceuticals
  • Transgene SA

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.07.24

Global Lymphoma Therapeutics Market to Reach US$25.2 Billion by 2030

The global market for Lymphoma Therapeutics estimated at US$16.1 Billion in the year 2023, is expected to reach US$25.2 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2023-2030. Non-Hodgkin Lymphoma (NHL) Therapeutics, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$20.5 Billion by the end of the analysis period. Growth in the Hodgkin Lymphoma (HL) Therapeutics segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 10.7% CAGR

The Lymphoma Therapeutics market in the U.S. is estimated at US$4.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 10.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Lymphoma Therapeutics - Key Trends and Drivers

Lymphoma therapeutics encompass a range of treatment options for lymphoma, a type of cancer that originates in the lymphatic system. There are two primary types of lymphoma: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), with the latter being more common. Treatment approaches for lymphoma have evolved significantly over the years, moving from traditional chemotherapy and radiation therapy to more targeted and effective options. Monoclonal antibodies, such as rituximab, have been game-changers, particularly for NHL, by targeting specific proteins on the surface of cancer cells. In addition, advancements in immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, have opened new avenues for treatment, offering hope for patients who do not respond to conventional therapies. These therapies harness the body’s immune system to fight cancer more effectively and have shown promising results in clinical trials, leading to increased survival rates and improved quality of life for patients.

Another significant advancement in lymphoma therapeutics is the development of targeted therapies, which focus on specific genetic mutations and cellular pathways involved in cancer progression. Drugs like brentuximab vedotin and ibrutinib have shown efficacy in treating various forms of lymphoma by interfering with cancer cell growth and survival mechanisms. These therapies are often used in combination with traditional treatments to enhance their effectiveness and reduce the likelihood of resistance. Additionally, advancements in diagnostic technologies, such as next-generation sequencing, have improved the ability to identify specific genetic alterations in lymphoma, enabling more personalized and precise treatment plans. This precision medicine approach not only improves outcomes but also minimizes side effects, as treatments can be tailored to the individual characteristics of each patient’s cancer.

The growth in the lymphoma therapeutics market is driven by several factors. Firstly, the increasing incidence of lymphoma, particularly in aging populations, has heightened the demand for effective treatment options. Secondly, technological advancements in biotechnology and pharmaceuticals have accelerated the development of novel therapies, expanding the arsenal of available treatments. Thirdly, the success of targeted therapies and immunotherapies has attracted significant investment in research and development, fostering a competitive and innovative market environment. Moreover, regulatory approvals of breakthrough therapies have streamlined the availability of advanced treatments to patients. Additionally, there is a growing awareness among patients and healthcare providers about the benefits of early diagnosis and personalized treatment approaches, which further drives market demand. Lastly, the expansion of healthcare infrastructure in emerging economies and the increasing adoption of advanced diagnostic and therapeutic technologies globally ensure sustained market growth. These factors collectively contribute to the dynamic and rapidly evolving landscape of lymphoma therapeutics, promising continued advancements and improved outcomes for patients.

Select Competitors (Total 93 Featured) -

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Forma Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Seattle Genetics, Inc.
  • Spectrum Pharmaceuticals
  • Transgene SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Lymphoma Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Lymphoma Propels Demand for Therapeutics
    • Advancements in Immunotherapy Spurs Growth in Lymphoma Treatment Options
    • Technological Innovations in Diagnostic Tools Expand Addressable Market Opportunity
    • Success of Targeted Therapies Strengthens Business Case for Precision Medicine
    • Growing Awareness of Early Diagnosis and Personalized Treatment Drives Adoption
    • Expansion of Healthcare Infrastructure in Emerging Economies Generates New Opportunities
    • Rising Aging Population Increases Demand for Lymphoma Treatments
    • Integration of Next-Generation Sequencing Throws the Spotlight on Precision Oncology
    • Combination Therapies Enhance Efficacy and Reduce Resistance in Lymphoma Treatment
    • Expansion of Clinical Trials Generates Insights and Accelerates Product Development
    • Enhanced Patient Awareness and Advocacy for New Treatments Generates Demand
    • Evolution of Treatment Guidelines Impact Market Trends
    • Advances in CAR-T Cell Therapy Expand Treatment Options for Refractory Cases
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Lymphoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma (NHL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Non-Hodgkin Lymphoma (NHL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Non-Hodgkin Lymphoma (NHL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hodgkin Lymphoma (HL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hodgkin Lymphoma (HL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hodgkin Lymphoma (HL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Revlimid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Revlimid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Revlimid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Rituxan / MabThera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Rituxan / MabThera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Rituxan / MabThera by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Imbruvica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Imbruvica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Imbruvica by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Keytruda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Keytruda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Keytruda by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Adcetris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Adcetris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Adcetris by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Lymphoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Lymphoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Lymphoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제